bretylium
Sign in to saveAlso known as ASL-603, bretylium tosylate, Bretylol®, 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, (2-bromobenzyl)ethyldimethylaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium, N-Ethyl-N,N-dimethyl-2-bromobenzenemethanaminium, (2-Bromobenzyl)ethyldimethylaminium
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy.
In the Vinony graph
Vinony's link graph records 824 inbound references to bretylium, and connects out to valproic acid, antiarrhythmic agent and (RS)-baclofen.
It is catalogued under topics including 2-Bromophenyl compounds, Adrenergic release inhibitors and Antiarrhythmic agents.
Vinony links it to 11 Wikipedia language editions.
Research
1,652 papers- Bretylium.2006
- Bretylium tosylate.American heart journal · 1971
- Bretylium tosylate: a review.American journal of hospital pharmacy · 1979
- Drug therapy: bretylium.The New England journal of medicine · 1979
- The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation.The American journal of cardiology · 2020
via PubMed
Wikidata facts
- Mass
- 242.054437
Show 3 more facts
- canonical SMILES
- CC[N+](C)(C)CC1=CC=CC=C1Br
- Commons category
- Bretylium
- chemical formula
- C₁₁H₁₇BrN⁺
via Wikidata · CC0
~3 min read
Encyclopedic overview
3 sectionsContents
- Uses
- Experimental uses
- References
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy.
Originally introduced in 1959 for the treatment of hypertension. Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota.
Excerpted from Wikipedia’s “bretylium” article, available under the CC BY-SA 4.0 licence.
Available in 11 languages
via Wikidata sitelinks · CC0